Johnson & Johnson med tech sales produced solid gains in 2013 as a whole, but divisions such as diabetes care and diagnostics slumped in Q4.
You know all those drugmakers promising a return to growth? Johnson & Johnson has them beat. The healthcare company kicked off pharma's year-end earnings season with overall sales growth of 6.1%--fueled, once again, by even bigger growth in its pharma business.
It's no revelation that pharma is behind the curve when it comes to social media. Consider yourselves fortunate, then, that the IMS Institute for Healthcare Informatics chose to delve into the subject. Its new report makes the case for social media--complete with the sort of statistics you'd want for your own memos to the powers that be.
A panel of FDA advisers voted 10-0 against recommending that Johnson & Johnson's Xarelto be approved to treat patients with acute coronary syndrome, marking the third such rejection for the treatment.
An FDA advisory panel left no room for interpretation Thursday as to whether it thought the FDA should approve Johnson & Johnson's Xarelto as a treatment for acute coronary syndrome, delivering its "no" loud and clear at the end of the daylong hearing.
Johnson & Johnson ($JNJ) agreed to unload its Ortho Clinical Diagnostics unit to the private equity firm Carlyle Group in a $4.15 billion deal.
After more than a year of less-than-clandestine sale efforts, Johnson & Johnson has found a buyer for its diagnostics unit, signing a $4.2 billion deal with Carlyle Group.
After becoming the worst-kept secret in the med tech world, Johnson & Johnson formally announced that Carlyle Group wants to buy its Ortho Clinical Diagnostics business for $4.15 billion.
Yesterday, Regeneron CEO Len Schleifer announced that r ather than the $377 million expected by analysts, Regeneron will report about $400 million in U.S. sales for macular degeneration treatment Eylea in the fourth quarter, Bloomberg reports.
Johnson & Johnson's innovation center in California will work with a Seattle diagnostics outfit on a biomarker discovery program geared toward spotting patients most likely to respond to targeted therapies.